Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders

Anti-MAG Neuropathy Clinical Trial

— THERAMAG  

Official title:

Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders:

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05136976
• Other study ID #: 19PH226
• Secondary ID: 2021-000009-25
• Status: Recruiting
• Phase: Phase 3
• Start date: June 29, 2023
• Est. completion date: December 2025

Study information

• Verified date: October 2023
• Source: Centre Hospitalier Universitaire de Saint Etienne
• Contact: Anne-Laure KAMINSKY, MD
• Phone: (0)4 77 82 95 10
• Email: a.laure.kaminsky[@]chu-st-etienne.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Anti-MAG neuropathy is a progressively disabling orphan rare disorder due to a monoclonal immunoglobulin M(IgM) gammopathy displaying reactivity toward MAG, a glycoprotein of the peripheral nervous system. Its prevalence is around 1/100000 and to date, no treatment has proven efficacy in this disease, including rituximab in 2 Randomized Controlled Trails(RCTs).

Description:

However these trials have included unselected anti-MAG patients and methodological issues have been raised.

In COFRAMAG study, the largest cohort worldwide of anti-MAG patients, predictors of clinical response to rituximab were identified through analysis of 92 treated patients: shorter disease duration and anti-MAG titre above 10000 BTU. Thus this study will focus on rituximab efficacy in a subset of patients with disease duration of less than 2 years and anti-MAG titre above 10000 Buhlmann Titer Units (BTU). The investigators selected Inflammatory Rasch-built Overall Disability Scale (I-RODS) as primary outcome measure because its responsiveness was proven higher than INCAT/ Overall Neuropathy Limitation Score (ONLS) scales to detect clinical meaningful changes in newly treated patients with inflammatory neuropathies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Disease duration of 24 months or less and documented clinical worsening (clinical or ENMG or disability) over the past 12 months

• IgM gammopathy, either MGUS or Waldenstrom Macroglobulinemia (WM)

• Demyelinating polyneuropathy according to European Federation of Neurological Societies/Peripheral Nerve Society guidelines for chronic inflammatory demyelinating polyneuropathy on nerve conduction studies.

• Anti-MAG titre of 10 000 BTU or more

• Total INCAT score of 1 point or more at baseline

• Absence of immunoglobulin treatment within 3 months prior to inclusion.

• Absence of immunosuppressive therapy within 6 months prior to inclusion, including steroid therapy of 2 months or more as part of the management of neuropathy.

• Negative ß-human chorionic gonadotropin (HCG) in women of childbearing potential

• Women of childbearing potential must agree to use contraception for 365 days following administration of rituximab.

Exclusion Criteria:

• - Unable to give informed consent

• History of severe allergic or anaphylactic reaction to chimeric monoclonal antibody

• Hypersensitivity known to one of the compounds of polaramine or methylprednisolone

• Previous treatment with rituximab

• Diseases known to cause polyneuropathy (e.g. diabetes, uncontrolled thyroid disease, vitamin B1 or B12 deficiency, renal (GFR < 60ml ml/min/1,73 m2- Modification of Diet in Renal Disease (MDRD) formula) or liver disorder, myeloma, amyloidosis, cryoglobulinemia)

• Indication of specific immunosuppressive therapy for WM

• Significant uncontrolled disease at baseline such as cardiovascular (including cardiac arrhythmia), pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine or gastrointestinal or any other significant disease that may prevent patient from participating in the study

• Congestive heart failure (NYHA III or IV)

• Known active bacterial, viral, fungal mycobacterial infection

• History or known presence of recurrent or chronic infection (e.g. viral hepatitis, HIV syphilis, tuberculosis).

• History of cancer, including solid tumors and haematological malignancies (except basal cell and in situ squamous carcinoma of the skin, in situ carcinoma of the cervix of the uterus that have been excised and resolved, with documented clear margins on pathology)

• History of alcohol (more than two drinks a day for a woman, more than 4 glasses a day for a man [World Health Organization (WHO) definition]) or other drug abuse within 6 months prior to randomization

• History or currently active primary or secondary immunodeficiency

• White blood cell count < 1500/mm3 or platelet count < 75 000/mm3

• Angle closure glaucoma,

• Urinary retention related to urethroprostatic disorders,

• Uncontrolled psychotic disorders,

• Severe liver failure,

• Recent vaccination with live vaccines (<3months) and vaccination with live virus vaccines is not recommended during the overall study period.

Related Conditions & MeSH terms

• Anti-MAG Neuropathy

Intervention

Drug:
• Rituximab infusion
2 infusions of 1 gram of rituximab at a 2 week interval (day 1 followed by day 15).
• Placebo infusion
2 infusions of placebo at a 2 week interval.
• Premedications
Premedications prior to rituximab or placebo infusions: IV Dexchlorpheniramine Maleate IV: 10 mg IV Methylprednisolone: 40 mg PO Paracetamol : 1 gram

Locations

Country	Name	City	State
France	CHU Brest - La cavale blanche	Brest
France	CHU Grenoble - La tronche	Grenoble
France	CHU Lille - Roger Salengro	Lille
France	CHU Limoges - Dupuytren	Limoges
France	HCL lyon	Lyon
France	CHU La Timone - APHM	Marseille
France	CHU Nancy- Hôpital central	Nancy
France	CHU Nice - Pasteur	Nice
France	APHP - Kremlin-Bicêtre	Paris
France	APHP Pitié Salpêtrière	Paris
France	CHU de Saint-Etienne	Saint-Étienne
France	CHU Strasbourg - Hautepierre	Strasbourg
France	CHU Toulouse - Pierre-Paul Riquet	Toulouse
France	CHU Tours - Bretonneau	Tours

Sponsors (2)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Saint Etienne	Ministry of Health, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	I-RODS score	Clinical response defined as a 4 points (or more) change of I-RODS between baseline and 12 months.; I-RODS is a 24-item patient-reported outcome measure which maximum score is 48. It is a linearly weighted scale that specifically captures activity and social participation limitations in patients with inflammatory neuropathies, including Monoclonal Gammopathy of Unknown Significance (MGUS) related polyneuropathies.	Baseline and 12 months
Secondary	Inflammatory Neuropathy Cause and Treatment (INCAT) disability score	The INCAT (Inflammatory Neuropathy Cause and Treatment) disability score is a measure of activity limitation with minimum score at 0 and maximum at 10.	Months: 0, 6, 12
Secondary	Six minute walk test	Six minute walk test will be realized.	Months : 0, 6, 12
Secondary	Timed 25- foot walk (FW) test	The T25-FW is a quantitative test of mobility and performance of leg function based on a timed outward journey of 25 steps, and a timed return journey of 25 steps. The score for the T25-FW is the average of the two completed trials	Months : 0, 6, 12
Secondary	9 hole peg test	The nine hole peg test is a standardized, quantitative assessment used to measure finger dexterity. Scores are based on the time taken to complete the test activity, recorded in seconds	Months : 0, 6, 12
Secondary	ElectroNeuroMyography (ENMG)	An ENMG will be realized.	Months : 0, 6, 12
Secondary	ENMG sensory sum score	ENMG sensory sum score will be realized.	Months : 0, 6, 12
Secondary	Score Motor unit number index (MUNIX)	Score MUNIX will be realised.	Months : 0, 6, 12
Secondary	Incidence of Treatment-Emergent Adverse Events of Rituximab	Consideration of adverse effects of Rituximab	Months : 0, 6, 12
Secondary	the anti-MAG antibody titre.	To study the correlation between the clinical response and the evolution of the anti-MAG antibody titre.	Months : 0, 6, 12